Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindBio TherapeuticsFRA:WF60 37 Net Current Asset Value is €-0.11 as of Mar. 2026. GuruFocus rates FRA:WF60 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 926 Biotechnology companies, MindBio Therapeutics ranks worse than 107991.25% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
MindBio Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was €-0.11.
The historical rank and industry rank for MindBio Therapeutics's Net Current Asset Value or its related term are showing as below:
FRA:WF60's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.95 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MindBio Therapeutics (FRA:WF60) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
MindBio Therapeutics Net Current Asset Value Related Terms
MindBio Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for MindBio Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindBio Therapeutics Net Current Asset Value Chart
FRA:WF60 vs VRTX, REGN, RVMD: Net Current Asset Value Comparison
For the Biotechnology subindustry, MindBio Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindBio Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where MindBio Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-0.11 mean?
MindBio Therapeutics (FRA:WF60) has a Net Current Asset Value of €-0.11 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on MindBio Therapeutics and its competitors. According to the industry distribution chart, MindBio Therapeutics ranks #999999 out of 926 companies in the Biotechnology industry.
Is MindBio Therapeutics' Net Current Asset Value too high?
MindBio Therapeutics' current Net Current Asset Value is €-0.11. Based on the distribution chart, MindBio Therapeutics ranks #999999 out of 926 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindBio Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindBio Therapeutics ranks #999999 out of 926 companies for Net Current Asset Value. This places MindBio Therapeutics in the lower half of its industry. The industry median Net Current Asset Value is 4.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.95, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on MindBio Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindBio Therapeutics's current Net Current Asset Value is €-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (FRA:WF60) has a current Net Current Asset Value of €-0.11. The current Net Current Asset Value is €-0.11. MindBio Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For MindBio Therapeutics (FRA:WF60), the current Net Current Asset Value is €-0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score
Get the complete analysis for FRA:WF60
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WF60 has been successfully added to your 
